Match!

Follow-up at 1 year and beyond of women with gestational diabetes treated with insulin and/or oral glucose-lowering agents: a core outcome set using a Delphi survey

Published on Jul 4, 2019in Diabetologia7.11
· DOI :10.1007/s00125-019-4935-9
Delia Bogdanet (NUI: National University of Ireland), Catriona Reddin (NUI: National University of Ireland)+ 20 AuthorsFidelma Dunne34
Estimated H-index: 34
(NUI: National University of Ireland)
Cite
Abstract
Aims/hypothesis Gestational diabetes mellitus (GDM) is linked with a higher lifetime risk for the development of impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, the metabolic syndrome, cardiovascular disease, postpartum depression and tumours. Despite this, there is no consistency in the long-term follow-up of women with a previous diagnosis of GDM. Further, the outcomes selected and reported in the research involving this population are heterogeneous and lack standardisation. This amplifies the risk of reporting bias and diminishes the likelihood of significant comparisons between studies. The aim of this study is to develop a core outcome set (COS) for RCTs and other studies evaluating the long-term follow-up at 1 year and beyond of women with previous GDM treated with insulin and/oral glucose-lowering agents.
  • References (23)
  • Citations (0)
Cite
References23
Newest
Published on Jan 5, 2019in Trials1.98
Delia Bogdanet1
Estimated H-index: 1
(National University of Ireland, Galway),
Aoife M. Egan11
Estimated H-index: 11
(National University of Ireland, Galway)
+ 6 AuthorsFidelma Dunne34
Estimated H-index: 34
(National University of Ireland, Galway)
Background Gestational diabetes (GDM) is associated with an increased lifetime risk for the development of glucose abnormalities, metabolic syndrome, cardiovascular disease, depression and tumours. Despite this high risk of additional comorbidities, there is no standardised approach to the long-term follow-up of women with a previous diagnosis of GDM. Also, there is no standardisation of outcome selection and reporting in studies involving this population. This increases the risk of reporting bi...
Published on Jun 1, 2019in Diabetologia7.11
Caroline K. Kramer2
Estimated H-index: 2
(MSH: Mount Sinai Hospital, Toronto),
Sara Campbell1
Estimated H-index: 1
(MSH: Mount Sinai Hospital, Toronto),
Ravi Retnakaran40
Estimated H-index: 40
(MSH: Mount Sinai Hospital, Toronto)
Aims/hypothesis Women who develop gestational diabetes mellitus (GDM) have an elevated lifetime risk of type 2 diabetes mellitus. Recently, a series of studies has suggested that women with GDM also have an increased risk of cardiovascular disease (CVD). However, it is unclear if this risk is dependent upon the intercurrent development of type 2 diabetes. Thus, we conducted a systematic review and meta-analysis to evaluate the impact of GDM on future risk of incident CVD and to ascertain the rol...
Published on Dec 1, 2017in Trials1.98
Elizabeth Gargon15
Estimated H-index: 15
(University of Liverpool),
Paula Williamson62
Estimated H-index: 62
(University of Liverpool)
+ 3 AuthorsMike Clarke87
Estimated H-index: 87
('QUB': Queen's University Belfast)
This letter describes the substantial activity on the Core Outcome Measure in Effectiveness Trials (COMET) website in 2015, updating our earlier progress reports for the period from the launch of the COMET website and database in August 2011 to December 2014. As in previous years, 2015 saw further increases in the annual number of visits to the website, the number of pages viewed and the number of searches undertaken. The sustained growth in use of the website and database suggests that COMET is...
Published on Aug 1, 2017in Cancer Causes & Control2.30
Paige D. Wartko3
Estimated H-index: 3
(UW: University of Washington),
Tiffany L. Beck3
Estimated H-index: 3
(UW: University of Washington)
+ 2 AuthorsStephen E. Hawes43
Estimated H-index: 43
(UW: University of Washington)
Purpose Excess circulating insulin may contribute to endometrial cancer (EC) development; studies suggest increased risk of EC associated with type 2 diabetes. We investigated whether gestational diabetes is associated with increased risk of EC and its precursor, endometrial hyperplasia (EH).
Published on Jun 16, 2017in Deutsches Arzteblatt International4.47
Hanne Melchior1
Estimated H-index: 1
,
Diana Kurch-Bek1
Estimated H-index: 1
,
Monika Mund3
Estimated H-index: 3
Published on Jun 1, 2017in BMJ Open2.38
Diane Farrar14
Estimated H-index: 14
(Bradford Royal Infirmary),
Mark Simmonds19
Estimated H-index: 19
(Ebor: University of York)
+ 4 AuthorsDebbie A. Lawlor112
Estimated H-index: 112
(UoB: University of Bristol)
Objective To investigate the effectiveness of different treatments for gestational diabetes mellitus (GDM). Design Systematic review, meta-analysis and network meta-analysis. Methods Data sources were searched up to July 2016 and included MEDLINE and Embase. Randomised trials comparing treatments for GDM (packages of care (dietary and lifestyle interventions with pharmacological treatments as required), insulin, metformin, glibenclamide (glyburide)) were selected by two authors and double checke...
Published on Nov 1, 2016in Gynecological Endocrinology1.41
Heidi Hakkarainen5
Estimated H-index: 5
,
Hanna Huopio13
Estimated H-index: 13
+ 3 AuthorsSeppo Heinonen10
Estimated H-index: 10
(HYKS: Helsinki University Central Hospital)
AbstractThe aim of this study was to evaluate the incidence of metabolic syndrome (MetS) during long-term follow-up of women with gestational diabetes (GDM). Furthermore, we evaluated the glycemic measures from an oral glucose tolerance test (OGTT) during pregnancy as predictors of incident MetS. Women diagnosed with GDM were divided into two groups according to the results of OGTT: one abnormal value = GDM1 (n = 338) and two abnormal values = GDM2 (n = 151), while women with normal glucose tole...
Published on Oct 18, 2016in PLOS Medicine
Jamie Kirkham26
Estimated H-index: 26
(University of Liverpool),
Sarah Gorst8
Estimated H-index: 8
(University of Liverpool)
+ 9 AuthorsPeter Tugwell105
Estimated H-index: 105
(U of O: University of Ottawa)
Background Core outcome sets (COS) can enhance the relevance of research by ensuring that outcomes of importance to health service users and other people making choices about health care in a particular topic area are measured routinely. Over 200 COS to date have been developed, but the clarity of these reports is suboptimal. COS studies will not achieve their goal if reports of COS are not complete and transparent. Methods and Findings In recognition of these issues, an international group that...
Published on Mar 1, 2015in Journal of Clinical Epidemiology4.65
Valerie Smith15
Estimated H-index: 15
(Trinity College, Dublin),
Mike Clarke87
Estimated H-index: 87
('QUB': Queen's University Belfast)
+ 1 AuthorsElizabeth Gargon15
Estimated H-index: 15
(University of Liverpool)
Abstract Objectives To survey the outcomes used in Cochrane Reviews, as part of our work within the Core Outcome Measures in Effectiveness Trials Initiative. Study Design and Setting A descriptive survey of Cochrane Reviews, divided by Cochrane Review Group (CRG), published in full for the first time in 2007 and 2011. Outcomes specified in the methods section of each review and outcomes reported in the results section of each review were of interest, in this exploration of the common use of outc...
Published on Dec 1, 2014in Trials1.98
Elizabeth Gargon15
Estimated H-index: 15
(University of Liverpool),
Paula Williamson62
Estimated H-index: 62
(University of Liverpool)
+ 2 AuthorsMike Clarke87
Estimated H-index: 87
The Core Outcome Measures in Effectiveness Trials (COMET) Initiative database is an international repository of studies relevant to the development of core outcome sets. By the end of 2013, it included a unique collection of 306 studies. The website is increasingly being used, with more than 12,000 visits in 2013 (a 55% increase over 2012), 8,369 unique visitors (a 53% increase) and 6,844 new visitors (a 48% increase). There has been a rise in visits from outside the United Kingdom, with 2,405 s...
Cited By0
Newest
View next paperOral anti-diabetic agents for women with pre-existing diabetes mellitus/impaired glucose tolerance or previous gestational diabetes mellitus